Cite
HARVARD Citation
Reck, M. et al. (2021). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. Journal of clinical oncology. 39 (21), pp. 2339-2349. [Online].